An Introduction to Macular Degeneration
The treatment landscape for macular degeneration is evolving with many new potential therapies under investigation. The standard of care in wet age-related macular degeneration (AMD) was revolutionised in 2005 with the introduction of anti-VEGF therapies, and current research into port delivery systems and drug combinations aim to provide longer-lasting treatments. Dry AMD is a challenging condition with no current treatment option, but research into stem cell therapies and drugs that slow the progression of geographic atrophy show much promise.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Macular Degeneration Content
Holistic approaches to patient care in nAMD
Watch this two-part activity discussing the latest developments in the clinical management of neovascular age-related macular degeneration (nAMD), filmed following the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review the key data on nAMD from the congress Watch Now Part 2: Choose from leading experts who discuss what the data means for global and regional practice Select An Interview
- Evaluate the use of retinal fluid as a marker of disease activity in neovascular age-related macular degeneration (nAMD)
- Recognize the impact of factors that contribute to treatment discontinuation and evaluate ways to reduce the treatment burden in nAMD
- Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-vascular endothelial growth factor (VEGF) therapy in nAMD
New Age-related Macular Degeneration Injectables
European Ophthalmic Review. 2020;14(1):17–20 DOI: https://doi.org/10.17925/EOR.2020.14.1.17
Modern treatments for wet age-related macular degeneration (wAMD) have progressed tremendously in the last decade, with the rise of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections as the standard-of-care. Both aflibercept (Eylea®, Regeneron, Tarrytown, NY, USA) and ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA) have become the gold standard for anti-VEGF agents. Initially, patients with […]
Assaf Hilely, ESCRS 2020 – Non-neovascular Age-related Macular Degeneration with Subretinal Fluid
We caught up with Editorial Board member Dr Assaf Hilely (Tel Aviv Medical Center, Tel Aviv, Israel), who talked us through his recent study of non-neovascular age-related macular degeneration with subretinal fluid. Questions What prognostic factors are currently used to guide treatment when initiating anti-vascular endothelial growth factor treatment for patients with age-related macular degeneration […]
Anat Loewenstein, EURETINA 2020 – The Importance of Home Monitoring
It was a pleasure to catch up with our Editorial Board member, Prof. Anat Loewenstein (Tel Aviv Medical Center, Israel), who talked to us about the importance of home monitoring in wet age-related macular degeneration. How has the COVID-19 pandemic affected the management of patients with wet age-related macular degeneration (AMD)? (0:10) How can home […]
Ramin Khoramnia, WOC 2020 – STAIRWAY Phase 2 Trial
Ramin Khoramnia (University Eye Clinic Heidelberg, Heidelberg, Germany) discusses imitations of current treatment options for neovascular age-related macular degeneration, gives an overview of faricimab, its dosing regimen and its mechanism of action and discusses the major efficacy and safety findings of the STAIRWAY study, which were presented at WOC 2020. 1. What are the limitations […]
The personalized patient experience in nAMD: What do the latest data tell us about optimizing clinical management?
Find out how the latest data on the clinical management of neovascular age-related macular degeneration (nAMD) from WOC2020 Virtual may influence clinical practice in a post-COVID-19 era in this series of interviews with experts from the USA, Europe and Asia.
- Evaluate strategies for the management of retinal fluid in nAMD
- Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-VEGF in nAMD
- Recall factors that contribute to optimization of clinical management and reduction in treatment burden for patients with nAMD
Gemmy Cheung Chui Ming, EURETINA 2019 – Clinical Characteristics of AMD
Gemmy Cheung Chui Ming (Singapore National Eye Centre) discusses the unmet needs in the field of AMD and the recent research into the differences in clinical characteristics of AMD in white and Asian patients. Questions: 1. What are the major unmet needs in the field of AMD? 2. What are the major differences in the […]
Will a scientific breakthrough translate into clinical benefits in nAMD? Highlights from EURETINA 2019
Review the latest developments in the management and treatment of patients with nAMD in this series of videos from the 19th EURETINA Congress 2019.
- Illustrate how retinal fluid may be used as a marker of disease activity and to guide individualized therapeutic strategy
- Define the importance of patient adherence to treatment on clinical outcomes and the factors that impact adherence and QoL
- Explain how smaller sized anti-VEGF antibodies may address the real-life unmet needs and confer clinical benefits
SOE 2019 – David Keegan – Implantable miniature telescope
David Keegan shares his experiences with the implantable miniature telescope for patients with AMD, and shares his tips on avoiding complications and helping patients with postoperative rehabilitation. Questions: 1. Could you tell us a little about the implantable miniature telescope and how it is implanted? 2. Which AMD patients are most likely to benefit from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!